Cargando…
Small Particle DEBIRI TACE as Salvage Therapy in Patients with Liver Dominant Colorectal Cancer Metastasis: Retrospective Analysis of Safety and Outcomes
The aim of this study was to examine the safety and efficacy of 40 µm and 75 µm calibrated irinotecan-eluting beads (DEBIRI-TACE) for the treatment of colorectal cancer metastases. We conducted a retrospective review of 36 patients with unresectable liver metastases from colorectal cancer who were t...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774320/ https://www.ncbi.nlm.nih.gov/pubmed/35049694 http://dx.doi.org/10.3390/curroncol29010020 |
_version_ | 1784636312908726272 |
---|---|
author | Voizard, Nicolas Ni, Tiffany Kiss, Alex Pugash, Robyn Raphael, Michael Jonathon Coburn, Natalie David, Elizabeth |
author_facet | Voizard, Nicolas Ni, Tiffany Kiss, Alex Pugash, Robyn Raphael, Michael Jonathon Coburn, Natalie David, Elizabeth |
author_sort | Voizard, Nicolas |
collection | PubMed |
description | The aim of this study was to examine the safety and efficacy of 40 µm and 75 µm calibrated irinotecan-eluting beads (DEBIRI-TACE) for the treatment of colorectal cancer metastases. We conducted a retrospective review of 36 patients with unresectable liver metastases from colorectal cancer who were treated with DEBIRI-TACE between 2017 to 2020. Patients who received at least one session of DEBIRI were included in our analysis. A total of 105 DEBIRI sessions were completed. 86% of patients (n = 31) underwent one round of treatment, 14% of patients (n = 5) underwent two distinct rounds of treatment. The majority of patients were discharged the next day (92%, n = 33 patients) with no 30-day post-DEBIRI mortality. Five high-grade adverse events occurred, including longer stay for pain management (n = 2), postembolization syndrome requiring readmission (n = 2), and liver abscess (n = 1). The average survival from diagnosis of metastatic disease was 33.3 months (range 11–95, median 28). Nine of 36 patients are still alive (December 2020) and have an average follow-up time of 36.8 months from T0 (range 12–63, median 39). Small particle DEBIRI is safe and well-tolerated in the salvage setting, with outcomes comparable to that of larger bead sizes. |
format | Online Article Text |
id | pubmed-8774320 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87743202022-01-21 Small Particle DEBIRI TACE as Salvage Therapy in Patients with Liver Dominant Colorectal Cancer Metastasis: Retrospective Analysis of Safety and Outcomes Voizard, Nicolas Ni, Tiffany Kiss, Alex Pugash, Robyn Raphael, Michael Jonathon Coburn, Natalie David, Elizabeth Curr Oncol Article The aim of this study was to examine the safety and efficacy of 40 µm and 75 µm calibrated irinotecan-eluting beads (DEBIRI-TACE) for the treatment of colorectal cancer metastases. We conducted a retrospective review of 36 patients with unresectable liver metastases from colorectal cancer who were treated with DEBIRI-TACE between 2017 to 2020. Patients who received at least one session of DEBIRI were included in our analysis. A total of 105 DEBIRI sessions were completed. 86% of patients (n = 31) underwent one round of treatment, 14% of patients (n = 5) underwent two distinct rounds of treatment. The majority of patients were discharged the next day (92%, n = 33 patients) with no 30-day post-DEBIRI mortality. Five high-grade adverse events occurred, including longer stay for pain management (n = 2), postembolization syndrome requiring readmission (n = 2), and liver abscess (n = 1). The average survival from diagnosis of metastatic disease was 33.3 months (range 11–95, median 28). Nine of 36 patients are still alive (December 2020) and have an average follow-up time of 36.8 months from T0 (range 12–63, median 39). Small particle DEBIRI is safe and well-tolerated in the salvage setting, with outcomes comparable to that of larger bead sizes. MDPI 2022-01-06 /pmc/articles/PMC8774320/ /pubmed/35049694 http://dx.doi.org/10.3390/curroncol29010020 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Voizard, Nicolas Ni, Tiffany Kiss, Alex Pugash, Robyn Raphael, Michael Jonathon Coburn, Natalie David, Elizabeth Small Particle DEBIRI TACE as Salvage Therapy in Patients with Liver Dominant Colorectal Cancer Metastasis: Retrospective Analysis of Safety and Outcomes |
title | Small Particle DEBIRI TACE as Salvage Therapy in Patients with Liver Dominant Colorectal Cancer Metastasis: Retrospective Analysis of Safety and Outcomes |
title_full | Small Particle DEBIRI TACE as Salvage Therapy in Patients with Liver Dominant Colorectal Cancer Metastasis: Retrospective Analysis of Safety and Outcomes |
title_fullStr | Small Particle DEBIRI TACE as Salvage Therapy in Patients with Liver Dominant Colorectal Cancer Metastasis: Retrospective Analysis of Safety and Outcomes |
title_full_unstemmed | Small Particle DEBIRI TACE as Salvage Therapy in Patients with Liver Dominant Colorectal Cancer Metastasis: Retrospective Analysis of Safety and Outcomes |
title_short | Small Particle DEBIRI TACE as Salvage Therapy in Patients with Liver Dominant Colorectal Cancer Metastasis: Retrospective Analysis of Safety and Outcomes |
title_sort | small particle debiri tace as salvage therapy in patients with liver dominant colorectal cancer metastasis: retrospective analysis of safety and outcomes |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774320/ https://www.ncbi.nlm.nih.gov/pubmed/35049694 http://dx.doi.org/10.3390/curroncol29010020 |
work_keys_str_mv | AT voizardnicolas smallparticledebiritaceassalvagetherapyinpatientswithliverdominantcolorectalcancermetastasisretrospectiveanalysisofsafetyandoutcomes AT nitiffany smallparticledebiritaceassalvagetherapyinpatientswithliverdominantcolorectalcancermetastasisretrospectiveanalysisofsafetyandoutcomes AT kissalex smallparticledebiritaceassalvagetherapyinpatientswithliverdominantcolorectalcancermetastasisretrospectiveanalysisofsafetyandoutcomes AT pugashrobyn smallparticledebiritaceassalvagetherapyinpatientswithliverdominantcolorectalcancermetastasisretrospectiveanalysisofsafetyandoutcomes AT raphaelmichaeljonathon smallparticledebiritaceassalvagetherapyinpatientswithliverdominantcolorectalcancermetastasisretrospectiveanalysisofsafetyandoutcomes AT coburnnatalie smallparticledebiritaceassalvagetherapyinpatientswithliverdominantcolorectalcancermetastasisretrospectiveanalysisofsafetyandoutcomes AT davidelizabeth smallparticledebiritaceassalvagetherapyinpatientswithliverdominantcolorectalcancermetastasisretrospectiveanalysisofsafetyandoutcomes |